Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-A1811 combination therapy in advanced HER2-expressing solid tumors
CTR20232390Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Aug 2023; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232390.